Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Fast Becoming World’s Pharmaceutical Formulation Factory

This article was originally published in PharmAsia News

Executive Summary

Zhejiang Huahai Pharmaceutical will cooperate with U.S. firm Enspire and invest $10 million to set up a new overseas company to develop, produce and sell soft capsules. Last July, Huahai gained U.S. FDA tentative approval to launch its anti-AIDS drug nevirapine in the U.S. in 2012, a first for a pharmaceutical company from China. In addition, it is China's only enterprise to receive FDA authorization for its solid pharmaceutical formulation workshop. Experts observe that currently fewer than 10 pharmaceutical firms in China have gained European and American certification. More than 20 companies are in the application stage and may receive licenses over the next two years. China's low-cost advantage attracts outsourcing by pharmaceutical MNCs and the country is poised to be the world's pharmaceutical formulation factory

You may also be interested in...

Deals Shaping The Medical Industry, April 2020

This month’s column covers deals announced between 1-23 April 2020. 

WHO Prequalifies Celltrion’s Rituximab

Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.

EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR – How To Survive Changing And Confusing Times

26 May 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts